Sorafenib induced pustular psoriasis in a patient of hepatocellular carcinoma: a rare case report

Authors

  • Saurabh Sharma Department of Dermatology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India
  • Roopam Bassi Department of Physiology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India
  • Manpreet Kaur Dr. Walia's Skin and Laser Clinic, Mohali, Punjab, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20181834

Keywords:

Pustular psoriasis, Sorafenib

Abstract

Pustular psoriasis is the least common form of psoriasis characterized by the formation of psoriatic plaques studded with pustules. Sorafenib is an oral multi-targeted kinase inhibitor approved for the management of hepatocellular carcinoma. We report a biopsy proven case of pustular psoriasis induced by Sorafenib in a patient of hepatocelluar carcinoma. Cutaneous adverse effects with Sorafenib are rare but are not life threatening. We are reporting this case because of the rarity of association and for highlighting the need for early detection and management.

Author Biographies

Saurabh Sharma, Department of Dermatology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India

Professor, Department of Dermatology

Roopam Bassi, Department of Physiology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India

Professor, Department of Physiology

Manpreet Kaur, Dr. Walia's Skin and Laser Clinic, Mohali, Punjab, India

Dermatolgist at Dr. Walia’s Skin and Laser Clinic, HM-127, Phase-3b1 Mohali

 

References

Augey G, Renaudier P, Nicolas JF. Generalized pustular psoriasis (zumbusch): a french epidemiological survey. Eur J Dermatol. 2006;16(6):669-73.

Swamy SG, Kameshwar VH, Shubha PB, Looi CY, Shanmugam MK, Arfuso F, et al. Target Oncol. 2017;12(1):1-10.

Muntané J, De la RAJ, Docobo F, García CR, Padillo FJ. Targeting tyrosine kinase receptors in hepatocellular carcinoma. Curr Cancer Drug Targets. 2013;13(3):300-12.

Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007;72(12):30-44.

Granito A, Marinelli S, Negrini G, Menetti S, Benevento F, Bolondi L. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol. 2016;9(2):240-9.

Yiu ZZ, Ali FR, Griffiths CE. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. Clin Exp Dermatol. 2016;41(4):407-9.

Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, et al. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014;53(3):376-84.

Burns T, Breathnach S, Cox N, Griffiths C. Rook’s Textbook of Dermatology. 8th ed. Singapore: Wiley-Blackwell; 2010.

Lopez AGM, Vela MCG, Yanez S, Llaca HF, Bernal JFV. Psoriasis form skin eruption associated with sorafenib therapy. Indian J Dermatol Venereol Leprol. 2011;77(5):614-5.

Du-Thanh A, Girard C, Pageaux GP, Guillot B, Dereure O. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type). Eur J Dermatol. 2013;23(6):900-1.

Nobuki M, Mayumi K, Yuka T, Takeo M, Satoru M, Mamitaro O. Pustular eruption induced by sorafenib in a case of psoriasis vulgaris. 2013;40(4):299–300.

Hsu MC, Chen CC. Psoriasis flare-ups following sorafenib therapy: A rare case. Dermatologica Sinica. 2016;34(3):148–50.

Downloads

Published

2018-04-25

Issue

Section

Case Reports